Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (DE:HDP1)
FRANKFURT:HDP1
RESEARCH TOOLSreports
Arrowhead Pharmaceuticals (HDP1) Stock Price & Analysis
0 Followers
HDP1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€19.52 - €37.16
Previous Close€20.28
Volume0.00
Average Volume (3M)124.00
Market Cap
€2.56B
Enterprise Value€2.53B
Total Cash (Recent Filing)$162.06M
Total Debt (Recent Filing)$118.58M
Price to Earnings (P/E)N/A
Beta0.64
Next Earnings
May 09, 2024EPS Estimate
-€0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding123,896,914
10 Day Avg. Volume0
30 Day Avg. Volume124
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)18.20
Price to Sales (P/S)156.09
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.93
Enterprise Value/Gross Profit10.52
Enterprise Value/Ebitda-9.53
Forecast
1Y Price Target
€52.43Price Target Upside158.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Arrowhead Pharmaceuticals News
PremiumCompany Announcements
Arrowhead Pharmaceuticals Appoints Dr. Hongbo Lu to BoardBulls Say, Bears Say
Bulls Say
Analyst EndorsementAnalyst reiterates a $90 price target and Buy rating on ARWR, with anticipation of positive outcomes in upcoming clinical trials, reflecting strong confidence in the stock's future performance.
Clinical Development ProgressEncouraging 48-week Phase 2b data support the advancement of plozasiran into a Phase 3 program, indicating a broader therapeutic potential and a significant step towards commercialization.
Pipeline PotentialArrowhead's cardiometabolic and pulmonary franchises are set to drive near-term value for shareholders, with early 2025 earmarked for its first potential commercial launch, signifying a major milestone for the company.
Bears Say
Drug DevelopmentEnded development of preclinical program ARO-SOD1 and partnered HZN-457 due to a lack of commercial viability.
Executive MovementThe departure of CMO Javier San Martin has led to a decision to decentralize his role and discontinue several preclinical programs.
Stock ValuationSell-off (-25%) and price target lowering from $60 to $50, accounts for balance sheet uncertainty.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.42% Other Institutional Investors
98.58% Public Companies and
Individual Investors
HDP1 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was €19.52 and its highest was €37.16 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 8 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Feb 06, 2024. The company reported -€1.158 earnings per share for the quarter, missing the consensus estimate of -€0.748 by -€0.41.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -€0.44.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Currently, no data Available
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -€1.158 in its last earnings report, missing expectations of -€0.748. Following the earnings report the stock price went down -2.2%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 41M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€52.43 (158.51% Upside)
€52.43 (158.51% Upside)
Blogger Sentiment
Bullish
DE:HDP1 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.72%
12-Months-Change
Fundamentals
Return on Equity
-110.45%
Trailing 12-Months
Asset Growth
-29.75%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
HDP1 Earnings Call
Q1 2024
0:00 / 0:00
---
HDP1 Stock 12 Months Forecast
Average Price Target
€52.43
▲(158.51% Upside)
Technical Analysis
Best Analysts Covering HDP1
1 Year
1 Year Success Rate
19/35 ratings generated profit
1 Year Average Return
+36.36%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 54.29% of your transactions generating a profit, with an average return of +36.36% per trade.
---